Chardan analyst Geulah Livshits raised the firm’s price target on Taysha Gene Therapies to $7 from $5 and keeps a Buy rating on the shares. The updated data on the two adult patients from cohort 1 of the Phase I/II REVEAL trial of intrathecal AAV9 gene therapy TSHA-102 for Rett syndrome show signals of sustained benefit as well as some new improvements, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSHA:
- Taysha Gene Therapies On Edge: The High Stakes of TSHA-102’s Regulatory Approval Journey
- Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
- Options Volatility and Implied Earnings Moves Today, March 19, 2024
- Options Volatility and Implied Earnings Moves This Week, March 18 – March 21, 2024
- Is TSHA a Buy, Before Earnings?
